Editorial: Targets for Immunotherapy in Acute Leukemia.
作者信息
Hourigan Christopher S
机构信息
Myeloid Malignancies Section, Hematology Branch National Heart, Lung and Blood Institute, National Institutes of Health Bethesda, MD 20892-1583. United States.
出版信息
Curr Drug Targets. 2017;18(3):256. doi: 10.2174/1389450117999151116144835.
Abstract
摘要
相似文献
1
Editorial: Targets for Immunotherapy in Acute Leukemia.社论：急性白血病免疫治疗的靶点
Curr Drug Targets. 2017;18(3):256. doi: 10.2174/1389450117999151116144835.
2
Prognostic Significance of Molecular Markers and Targeted Regimens in the Management of Acute Myeloid Leukemia.分子标志物与靶向治疗方案在急性髓系白血病治疗管理中的预后意义。
J Natl Compr Canc Netw. 2018 May;16(5S):656-659. doi: 10.6004/jnccn.2018.0050.
3
Moving forward in target antigen discovery for immunotherapy in acute myeloid leukemia.推进急性髓系白血病免疫治疗中靶抗原的发现
Haematologica. 2024 Oct 1;109(10):3088-3090. doi: 10.3324/haematol.2023.284894.
4
Immune therapy of AML.急性髓系白血病的免疫治疗。
Cytotherapy. 2002;4(5):437-8. doi: 10.1080/146532402320776099.
5
Novel drug targets in acute leukemia.急性白血病中的新型药物靶点
Clin Adv Hematol Oncol. 2015 Aug;13(8):493-5.
6
Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia.急性髓系白血病免疫治疗的新型抗原靶点
Curr Drug Targets. 2017;18(3):296-303. doi: 10.2174/1389450116666150223120005.
7
Current strategies in immunotherapy for acute myeloid leukemia.急性髓细胞白血病的免疫治疗策略。
Immunotherapy. 2013 Jan;5(1):63-78. doi: 10.2217/imt.12.145.
8
Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia.白血病相关抗原及其与急性髓细胞白血病免疫治疗的相关性。
Leukemia. 2012 Oct;26(10):2186-96. doi: 10.1038/leu.2012.145. Epub 2012 Jun 1.
9
Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.免疫疗法治疗急性髓细胞白血病（AML）：一种强有力的替代疗法。
Biomed Pharmacother. 2018 Jan;97:225-232. doi: 10.1016/j.biopha.2017.10.100. Epub 2017 Nov 6.
10
Advances in acute myeloid leukemia.急性髓细胞白血病的研究进展。
BMJ. 2021 Oct 6;375:n2026. doi: 10.1136/bmj.n2026.
引用本文的文献
1
SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints.SETD2 突变通过改变细胞周期检查点部分赋予急性髓系白血病的化疗耐药性。
Leukemia. 2019 Nov;33(11):2585-2598. doi: 10.1038/s41375-019-0456-2. Epub 2019 Apr 9.
本文引用的文献
1
Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells.采用体外扩增T细胞进行白血病的过继性免疫治疗。
Curr Drug Targets. 2017;18(3):271-280. doi: 10.2174/1389450117666160209143529.
2
Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.免疫调节药物：急性白血病中的免疫检查点抑制剂
Curr Drug Targets. 2017;18(3):315-331. doi: 10.2174/1389450116666150518095346.
3
Do We Need Full Donor Chimerism? How Alloreactive Cell Therapies without Substantial Engraftment Might Treat Hematologic Cancers.我们需要完全供体嵌合状态吗？没有大量植入的同种异体反应性细胞疗法如何治疗血液系统癌症。
Curr Drug Targets. 2017;18(3):281-295. doi: 10.2174/1389450116666150304103849.
4
Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML).免疫调节药物：急性髓系白血病（AML）中的免疫调节药物（IMiDs）
Curr Drug Targets. 2017;18(3):304-314. doi: 10.2174/1389450116666150304104315.
5
Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia.急性髓系白血病免疫治疗的新型抗原靶点
Curr Drug Targets. 2017;18(3):296-303. doi: 10.2174/1389450116666150223120005.
6
T-cell adoptive immunotherapy for acute lymphoblastic leukemia.用于急性淋巴细胞白血病的T细胞过继性免疫疗法。
Hematology Am Soc Hematol Educ Program. 2013;2013:348-53. doi: 10.1182/asheducation-2013.1.348.
7
Nivolumab plus ipilimumab in advanced melanoma.纳武利尤单抗联合伊匹单抗治疗晚期黑色素瘤。
N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.
8
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.用表达抗 CD19 嵌合抗原受体的 T 细胞治疗 B 细胞癌。
Nat Rev Clin Oncol. 2013 May;10(5):267-76. doi: 10.1038/nrclinonc.2013.46. Epub 2013 Apr 2.
9
Evaluation of current cancer immunotherapy: hemato-oncology.当前癌症免疫疗法评估：血液肿瘤学。
Cancer J. 2011 Sep-Oct;17(5):309-24. doi: 10.1097/PPO.0b013e3182341fde.
Zotero 插件